
Global R&D Pipeline
My Favorite
Hot Targets:
NaPi-2b
Back
Total number of drugs
25
Phase II and later clinical stages
12%
Involving companies
23
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LM-001(LaNova Medicines) | LM-001(LaNova Medicines) | Antibody drug conjugate (ADC) ADC | Neoplasms Endocrinology and Metabolic Disease Respiratory Diseases Urogenital Diseases | Sodium-dependent phosphate transport protein 2B inhibitors | LaNova Medicines Ltd. | Preclinical | Preclinical | LM-001(LaNova Medicines) | detail > | ||||||||||||
| NaPi-2b inhibitors(Kyowa Kirin) | NaPi-2b inhibitors(Kyowa Kirin) | Small molecule drug | Endocrinology and Metabolic Disease | Sodium-dependent phosphate transport protein 2B inhibitors | Kyowa Kirin Co., Ltd. | Kyowa Kirin Co., Ltd. | Preclinical | NaPi-2b inhibitors(Kyowa Kirin) | detail > | ||||||||||||
| NaPi2b-PL2202 | NaPi2b-PL2202 | Antibody drug conjugate (ADC) ADC | Neoplasms Endocrinology and Metabolic Disease Respiratory Diseases Urogenital Diseases | Sodium-dependent phosphate transport protein 2B inhibitors DNA topoisomerase I inhibitors | ADC Therapeutics SA | ADC Therapeutics SA | Preclinical | Val-Ala | Exatecan 依喜替康 | 6 | NaPi2b-PL2202 | detail > | |||||||||
| XMT-1592 | XMT-1592 | Antibody drug conjugate (ADC) ADC | Neoplasms Respiratory Diseases | Sodium-dependent phosphate transport protein 2B inhibitors Tubulin inhibitors | Mersana Therapeutics, Inc. | Mersana Therapeutics, Inc. | Preclinical | Protease cleavable linker 酶裂解 | AF-HPA | 6 | XMT-1592 | IgG1 - nd | asparagine 天冬酰胺 | detail > | |||||||
| ZW-220 | ZW-220 | Antibody drug conjugate (ADC) ADC | Neoplasms Endocrinology and Metabolic Disease Respiratory Diseases Urogenital Diseases | Sodium-dependent phosphate transport protein 2B inhibitors DNA topoisomerase I inhibitors | Zymeworks BC, Inc. | Zymeworks, Inc. | Preclinical | MC-GGFG | ZD06519 | 4-8 | ZW-220 | IgG1 - nd | cysteinyl 半胱氨酸 | detail > | |||||||
| Upifitamab | Upifitamab | Monoclonal antibody | Sodium-dependent phosphate transport protein 2B inhibitors | Mersana Therapeutics, Inc. | Mersana Therapeutics, Inc. | Discovery | Upifitamab | detail > | |||||||||||||
| Lifastuzumab vedotin | Lifastuzumab vedotin | Antibody drug conjugate (ADC) ADC | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases Respiratory Diseases | Sodium-dependent phosphate transport protein 2B inhibitors Tubulin inhibitors | Genentech, Inc. | Phase 2 | Lifastuzumab | Mc-Val-Cit-PABC-PNP | MMAE 甲基澳瑞他汀E | 3-4 | Lifastuzumab vedotin | IgG1 - kappa | cysteinyl 半胱氨酸 | detail > | |||||||
| 99mTc-Rebmab200 | 99mTc-Rebmab200 | Radiolabeled antibody Diagnostic radiopharmaceuticals | Neoplasms Endocrinology and Metabolic Disease Urogenital Diseases | Sodium-dependent phosphate transport protein 2B inhibitors | Recepta Biopharma SA | Preclinical | 99m Tc | 99mTc-Rebmab200 | detail > | ||||||||||||
| RebmAb200 | RebmAb200 | Monoclonal antibody | Neoplasms | Sodium-dependent phosphate transport protein 2B inhibitors | Recepta Biopharma SA | Preclinical | RebmAb200 | detail > | |||||||||||||
| ASP-3325 | ASP-3325 | Small molecule drug | Endocrinology and Metabolic Disease Urogenital Diseases | Sodium-dependent phosphate transport protein 2B inhibitors | Astellas Pharma, Inc. | Phase 1 | ASP-3325 | detail > |
Total 25 data
1
2
3


